Industry
Avadel
Total Trials
5
Recruiting
1
Active
2
Completed
3
Success Rate
100.0%+13% vs avg
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
Failure Rate
0.0%
0 terminated/withdrawn out of 5 trials
Success Rate
100.0%
+13.5% vs industry average
Late-Stage Pipeline
60%
3 trials in Phase 3/4
Results Transparency
33%
1 of 3 completed trials have results
Key Signals
1 recruiting1 with results
Enrollment Performance
Analytics
Phase 3
3(75.0%)
Phase 2
1(25.0%)
4Total
Phase 3(3)
Phase 2(1)
Activity Timeline
Global Presence
Loading network data...
Clinical Trials (5)
Showing 5 of 5 trials
NCT06792708Completed
Observational Study of LUMRYZ in Narcolepsy
Role: lead
NCT06525077Phase 3Active Not Recruiting
Safety and Efficacy of FT218 in Idiopathic Hypersomnia (REVITALYZ)
Role: lead
NCT06809803Phase 2Recruiting
Extended-release Sodium Oxybate in Children
Role: collaborator
NCT04451668Phase 3Completed
An Open Label Study of FT218 in Subjects With Narcolepsy
Role: lead
NCT02720744Phase 3Completed
Once-Nightly Sodium Oxybate for Treatment of Excessive Daytime Sleepiness and Cataplexy in Narcolepsy
Role: lead
All 5 trials loaded